As an overview, the profile of suitable T1DM patients for SGLT-2is associated with AID therapy includes overweighting/obesity (BMI > 27 kg/m2), insulin resistance (>0.5 Units/kg), metabolic syndrome, hyperglycemia despite optimized insulin therapy, desire for blood pressure control along with achieving euglycemia, albuminuria, and diabetic nephropathy, and difficulties in reaching TIR > 70%. This evidence concerns the gene INS and type 1 diabetes mellitus.